Eupraxia Pharmaceuticals’ (EPRX) Buy Rating Reiterated at HC Wainwright

Eupraxia Pharmaceuticals (NASDAQ:EPRX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 45.70% from the stock’s current price.

A number of other research firms also recently weighed in on EPRX. Zacks Research downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. William Blair started coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They set an “outperform” rating on the stock. Cantor Fitzgerald lifted their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Eupraxia Pharmaceuticals Trading Down 4.3%

Eupraxia Pharmaceuticals stock traded down $0.34 on Monday, reaching $7.55. 48,504 shares of the stock were exchanged, compared to its average volume of 210,713. The firm has a fifty day moving average price of $7.43 and a two-hundred day moving average price of $7.19. The stock has a market cap of $456.25 million, a PE ratio of -7.33 and a beta of 1.19. Eupraxia Pharmaceuticals has a twelve month low of $3.67 and a twelve month high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Equities analysts anticipate that Eupraxia Pharmaceuticals will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter valued at about $71,000. Bank of America Corp DE increased its position in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the period. Guardian Wealth Advisors LLC NC acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $76,000. Aptus Capital Advisors LLC acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $76,000. Finally, Geode Capital Management LLC acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $105,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.